Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON.

Ophthalmology and therapy·2026
Same author

Correlation between blood glucose levels and endophthalmitis risk after intravitreal injections of anti-vascular endothelial growth factor.

Eye (London, England)·2026
Same author

Diagnostic accuracy of echocardiography in identifying heart failure related pleural effusions.

Respiratory medicine·2026
Same author

Incidence of Conjunctivitis and Keratitis with Reusable Ophthalmic Laser Lenses at an Academic Medical Center.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same author

Medicaid Accessibility for Ophthalmologists and Optometrists in Florida: A Pilot Study.

Cureus·2025
Same author

Factors determining compliance with recommended intravitreal injections for retinal diseases among out-of-pocket, fully subsidized (non-paying), and insured patients: Real-world evidence from India.

Indian journal of ophthalmology·2025
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026
Same journal

Pulsatile FXR agonism.

Nature reviews. Drug discovery·2026
Same journal

CRISPR strategy tackles bacterial toxin.

Nature reviews. Drug discovery·2026
Same journal

Time to peak sales: how long is the climb?

Nature reviews. Drug discovery·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Aflibercept.

Michael W Stewart, Seden Grippon, Peter Kirkpatrick

    Nature Reviews. Drug Discovery
    |March 31, 2012
    PubMed
    Summary
    This summary is machine-generated.

    Aflibercept (Eylea) is a novel biologic therapy approved for neovascular age-related macular degeneration. This vascular endothelial growth factor inhibitor offers a new treatment option for patients.

    Related Experiment Videos

    Last Updated: May 23, 2026

    Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
    10:18

    Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

    Published on: July 7, 2023

    Area of Science:

    • Ophthalmology
    • Pharmacology
    • Biotechnology

    Background:

    • Neovascular age-related macular degeneration (AMD) is a leading cause of vision loss.
    • Vascular Endothelial Growth Factor (VEGF) plays a critical role in the pathogenesis of wet AMD.
    • Limited effective treatments were available prior to 2011.

    Discussion:

    • Aflibercept targets multiple VEGF family members, offering a broad mechanism of action.
    • Its approval marks a significant advancement in managing wet AMD.
    • The drug's efficacy and safety profile are crucial for clinical adoption.

    Key Insights:

    • Aflibercept (Eylea) received FDA approval in November 2011 for neovascular AMD.
    • It functions as a recombinant fusion protein inhibiting VEGF.
    • This biologic therapy represents a new frontier in retinal disease treatment.

    Outlook:

    • Further research will explore aflibercept's long-term outcomes and potential in other VEGF-mediated diseases.
    • Comparative studies with existing therapies will refine treatment strategies.
    • The development of targeted biologic therapies continues to advance ophthalmology.